Drug Trial Radar · NCT05095844
National Vaccine Adverse Event Reporting Survey and Etiology
Last checked: Nov 19, 2026Latest source record: Mar 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100,000
Planned (sponsor's estimate)
Start
Mar 15, 2022
Primary completion
Apr 1, 2024
Study completion Apr 1, 2024
Sponsor
- Lead sponsor
- Neuroganics LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Ramos Injury Law Firm
- First posted
- Oct 27, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms. The primary goal of this study is to create a national database and gather vaccine-associated serious adverse events/injury data from newly vaccinated individuals in the US in order to identify the possible underlying causal relationships and plausible underlying biological mechanisms. The project aims to identify the genetic determinants of vaccine-induced adverse response by studying host genetics. We plan to use whole genome sequencing to identify single nucleotide polymorphisms associated with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological symptoms induced by vaccine administration. The secondary goal is to establish criteria that enable classification of vaccine-induced adverse events/injuries compare data from our database with the official Vaccine Injury Table National Vaccine Injury Compensation Program on or after March 21, 2017. The tertiary goal is to establish a database to gather detailed long-term adverse reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical trials.
Conditions
- COVID-19
- Vaccine Adverse Reaction
- Vaccine Reaction
- Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Corona Virus Infection
- Blood Clot
- Thrombocytopenia
- Neuritis
- Vasculitis
- Influenza
- Guillain-Barré
- GWAS
- Genetic Sequencing
Interventions
vaccinatedBiological
Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neuroganics LLC
Northglenn, Colorado · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.